Literature DB >> 986357

Production of antisera to synthetic benzyloxycarbonyl-C-peptide of human proinsulin.

O K Faber, J Markussen, V K Naithani, C Binder.   

Abstract

Antisera to the C-peptide of human proinsulin were obtained by immunizing guinea pigs with synthetic benzyloxycarbonyl-C-peptide conjugated to human albumin with 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. In three series of 10, the animals were injected with C-peptide conjugated to albumin in the molar ratio of 23 : 1, 15 : 1, and 4 : 1, respectively. Antibodies to human C-peptide were present in all the surviving 25 animals. Fifteen of the antisera were suitable for measuring C-peptide concentrations lower than 0.10 pmol/ml. The antisera demonstrated an increasing immunogenicity with increasing molar ratio of C-peptide to albumin in the conjugate. In the fourth series, ten guinea pigs immunized with benzyloxycarbonyl-C-peptide ionically bound to QAE-Sephadex A-25 did not produce detectable antibodies to C-peptide. A qualitative evaluation of the radioimmunoassay by use of the antiserum with the highest titer and sensitivity, "M 1230", revealed a mean intra-assay and inter-assay coefficient of variance of 3.2 and 9.6%, respectively.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 986357     DOI: 10.1515/bchm2.1976.357.1.751

Source DB:  PubMed          Journal:  Hoppe Seylers Z Physiol Chem        ISSN: 0018-4888


  30 in total

1.  B-cell function and blood glucose control in insulin dependent diabetics within the first month of insulin treatment.

Authors:  O K Faber; C Binder
Journal:  Diabetologia       Date:  1977-05       Impact factor: 10.122

2.  High heritability and genetic correlation of intravenous glucose- and tolbutamide-induced insulin secretion among non-diabetic family members of type 2 diabetic patients.

Authors:  Anette P Gjesing; Malene Hornbak; Kristine H Allin; Claus T Ekstrøm; Søren A Urhammer; Hans Eiberg; Oluf Pedersen; Torben Hansen
Journal:  Diabetologia       Date:  2014-03-07       Impact factor: 10.122

3.  Rapid changes in plasma androgens during insulin withdrawal in male type 1 (insulin-dependent) diabetics.

Authors:  S Madsbad; C Gluud; P Bennett; T Krarup
Journal:  J Endocrinol Invest       Date:  1986-02       Impact factor: 4.256

4.  Fasting and oral glucose-stimulated levels of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) are highly familial traits.

Authors:  A P Gjesing; C T Ekstrøm; H Eiberg; S A Urhammer; J J Holst; O Pedersen; T Hansen
Journal:  Diabetologia       Date:  2012-02-15       Impact factor: 10.122

5.  How does glucose regulate the human pancreatic A cell in vivo?

Authors:  C M Asplin; P M Hollander; J P Palmer
Journal:  Diabetologia       Date:  1984-03       Impact factor: 10.122

6.  Kinetics of human connecting peptide in normal and diabetic subjects.

Authors:  O K Faber; C Hagen; C Binder; J Markussen; V K Naithani; P M Blix; H Kuzuya; D L Horwitz; A H Rubenstein; N Rossing
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

7.  Secretion and processing of insulin precursors in yeast.

Authors:  L Thim; M T Hansen; K Norris; I Hoegh; E Boel; J Forstrom; G Ammerer; N P Fiil
Journal:  Proc Natl Acad Sci U S A       Date:  1986-09       Impact factor: 11.205

8.  Persistent insulin secretion, assessed by plasma C-peptide estimation in long-term juvenile diabetics with a low insulin requirement.

Authors:  C Eff; O Faber; T Deckert
Journal:  Diabetologia       Date:  1978-09       Impact factor: 10.122

9.  The effect of residual insulin secretion on exocrine pancreatic function in juvenile-onset diabetes mellitus.

Authors:  B M Frier; O K Faber; C Binder; H L Elliot
Journal:  Diabetologia       Date:  1978-05       Impact factor: 10.122

10.  Proinsulin levels in newborn siblings of type 1 (insulin-dependent) diabetic children and their mothers.

Authors:  F A Lindgren; S G Hartling; B E Persson; M E Röder; K Snellman; C Binder; G Dahlquist
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.